A marine-derived acidic oligosaccharide sugar chain specifically inhibits neuronal cell injury mediated by beta-amyloid-induced astrocyte activation in vitro.
In Alzheimer's disease (AD), beta-amyloid (Abeta) plaques are surrounded by activated astrocytes and microglia. A growing body of evidence suggests that these activated astrocytes contribute to neurotoxicity through the induction of inflammatory cytokines and the production of oxidative stress mediators. Thus, a compound inhibiting Abeta-induced activation of astrocytes may lead to a novel therapy for AD. Our current work investigates the roles of acidic oligosaccharide sugar chain (AOSC), derived from brown algae Echlonia Kurome Okam, on Abeta-induced inflammatory responses and cytotoxicity. We observed that AOSC inhibited the toxicity and apoptosis in SH-SY5Y cell line induced by Abeta-stimulated astrocytes conditioned medium. We found that AOSC inhibited the reactive phenotype of astrocytes, blocked cellular oxidative stress, reduced the production of tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 and prevented the influx of Ca2+. Thus, our results indicate that AOSC might be a potentially therapeutic compound for AD.
Wang
Shaohua
S
Department of Pharmacology, Marine Drug and Food Institute, Ocean University of China, Qingdao 266003, China.
Li
Jing
J
Xia
Wei
W
Geng
Meiyu
M
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors* / Q000633:toxicity; D000818:Animals; D000831:Animals, Newborn; D001253:Astrocytes / Q000187:drug effects* / Q000378:metabolism; D020013:Calcium Signaling / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D017077:Culture Media, Conditioned / Q000494:pharmacology; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000378:metabolism; D004660:Encephalitis / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D005911:Gliosis / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D015850:Interleukin-6 / Q000378:metabolism; D008351:Mannans / Q000494:pharmacology* / Q000627:therapeutic use; D009410:Nerve Degeneration / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D018384:Oxidative Stress / Q000187:drug effects / Q000276:immunology; D051381:Rats; D017208:Rats, Wistar; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D016229:Amyloid beta-Peptides; D017077:Culture Media, Conditioned; D016207:Cytokines; D015850:Interleukin-6; D008351:Mannans; D014409:Tumor Necrosis Factor-alpha; C500727:acidic oligosaccharide sugar chain, Echlonia Kurome Okam